Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized open-label study of aripiprazole versus other atypical antipsychotics on metabolic parameters in schizophrenia
2007-001217-42Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia and cardiometabolic risk (CMR) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean percentage change in fasting non-HDL cholesterol at Week 16 (LOCF). Started Aug 2007; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniacardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2007-001217-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001217-42.